NCT04110275View on ClinicalTrials.gov

Injection of Recombinant Human Tissue-type Plasminogen Activator Derivative for Acute Pulmonary Embolism(rPA)

PHASE2UnknownINTERVENTIONAL
Enrollment

174

Participants

Timeline

Start Date

October 31, 2019

Primary Completion Date

May 31, 2021

Study Completion Date

August 31, 2021

Conditions
Acute Pulmonary Embolism
Interventions
DRUG

Recombinant human tissue-type plasminogen activator derivative

Recombinant human tissue-type plasminogen activator derivative(rPA,chemical name: Reteplase,brand name:Ruitongli) 18mg/10ml/stick, provided by AngDe Biotech Pharmaceutical Co.,LIMITED(LTD)

DRUG

Recombinant human tissue-type plasminogen activator

Recombinant human tissue-type plasminogen activator(rt-PA,chemical name:Alteplase,brand name: Actilyse)50mg/stick,provided by Boehringer Ingelheim Pharma Gesellschaft mit beschrankter Haftung(GmbH)\&Co,

Sponsors
All Listed Sponsors
lead

Angde Biotech Pharmaceutical Co., Ltd.

INDUSTRY

NCT04110275 - Injection of Recombinant Human Tissue-type Plasminogen Activator Derivative for Acute Pulmonary Embolism(rPA) | Biotech Hunter | Biotech Hunter